Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Metoprolol succinate was given to 60 patients with class I-III heart failure and ejection fraction <45% after myocardial infarction. Forty seven patients (mean age 59.3+/-9.8 years) completed 6 months of therapy. Dynamics of ventricular arrhythmias was assessed by Holter ECG monitoring, registration of parameters of high resolution ECG and heart rate variability. and echocardiography. Functional class of heart failure decreased in 93%, that of angina - in 55% of patients. Antiarrhythmic effect was achieved in 72% of patients. This was associated with diminishment of left ventricular volumes and increased ejection fraction, shortening of TotQRSF, and improvement of autonomic regulation of cardiac action. No dynamics of myocardial contractility and electrophysiological remodeling occurred in patients without antiarrhythmic effect.
 ...
PMID:[Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure]. 1289 11

Metoprolol succinate is a widely used medication for the management of hypertension, heart failure, and angina. We report the case of a 36-year-old woman who developed erythema multiforme after administration of a low dose of this drug. She also presented with pruritic burning pain throughout her body accompanied by chills. While erythema multiforme has been reported with carvedilol, this is the first observation of metoprolol succinate causing this and physicians should be aware of this potential, yet rare, side-effect.
 ...
PMID:Metoprolol succinate therapy associated with erythema multiforme. 1913 Apr 21

Metoprolol succinate, carvedilol, and bisoprolol are approved for use in heart failure. Other beta-blockers have been found to be inferior (metoprolol tartrate) or have not been studied (atenolol). The authors compared all-cause mortality following treatment with either atenolol, carvedilol, or metoprolol tartrate for 974 patients with left ventricular function < or =40%. The unadjusted mortality at 6 months was lower with atenolol (3.2%) and carvedilol (4.2%) when compared with metoprolol tartrate (7.5%, P< or =.039). However, patients with atenolol were older but had less prior heart failure. After adjustment for the propensity to be treated with atenolol, patients actually treated with atenolol had a significantly lower risk of death compared with treatment with metoprolol tartrate and comparable outcome to those treated with carvedilol. These results suggest that atenolol may be useful for patients with heart failure treatment and highlight the need for a randomized trial comparing atenolol with established beta-blockers.
 ...
PMID:Survival among patients with left ventricular systolic dysfunction treated with atenolol. 1975 21

Metoprolol succinate is a selective beta-adrenergic receptor blocker useful in treatment of hypertension, angina and heart failure. The purpose of the present work was to design and evaluate controlled release matrix type tablet of Metoprolo succinate using HPMC K15M and Eudragit (RLPO and RSPO) as a matrix forming agents. Effect of various polymer alone and combinations were studied in pH 1.2 buffer using USP type II paddle at 50 rpm. HPMC was used to form firm gel with Eudragit polymer. Formulation with Equal proportion (1:1) of Eudragit RSPO and RLPO showed optimum drug release t(50)=7 hrs and t(100)=16 hrs indicate optimum permeability for drug release from matrix. The drug release mechanism was predominantly found to be Non-Fickian diffusion controlled.
 ...
PMID:Design and characterization of controlled release tablet of metoprolol. 2306 22